A Randomized Controlled Trial to Evaluate Efficacy and Safety of Thymosin-α1 Administration in Patients With HBV-related Acute-on-chronic Liver Failure
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Thymalfasin (Primary)
- Indications Liver failure
- Focus Therapeutic Use
- 29 Aug 2020 Primary endpoint (The survival rate of 24 weeks) has been met.
- 29 Aug 2020 Results presented at The International Liver Congress 2020.
- 11 May 2020 Status changed from not yet recruiting to completed.